Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Silexion Therapeutics Corp (NASDAQ:SLXN) announced Thursday it has regained compliance with Nasdaq Capital Market listing requirements, following confirmation from The Nasdaq Stock Market LLC. The company reported it received a letter from Nasdaq on Monday confirming that Silexion now meets both the minimum shareholders’ equity requirement of $2.5 million and the minimum $1.00 per share bid price rule.
According to the company’s statement, Silexion increased its shareholders’ equity to approximately $9.41 million as of September 15, 2025, after completing a series of financing transactions. The company had previously been granted an extension by the Nasdaq Hearings Panel on July 7, 2025, to demonstrate compliance by September 19, 2025.
Silexion also addressed a previous deficiency in its share price, which had fallen below the $1.00 minimum for 30 consecutive business days. The company conducted a 1-for-15 reverse share split on July 29, 2025, following shareholder approval, which resulted in the closing price of its ordinary shares remaining above the $1.00 threshold.
Nasdaq’s confirmation letter states that Silexion is now in compliance with both the equity and minimum bid price requirements for continued listing on the Nasdaq Capital Market. The company will remain subject to a mandatory panel monitor until September 23, 2026. If Silexion falls out of compliance with the equity requirement during this one-year period, Nasdaq would issue a delisting determination, and the company would have the opportunity to request a new hearing.
The information in this article is based on a statement provided in a press release and a filing with the U.S. Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.